Three new studies, one clear goal: to rethink the early detection and prevention of breast cancer – individually, precisely and non-invasively.
The research led by Prof. Martin Widschwendter’s team shows how epigenetic markers in a simple mouth swab can provide indications of individual risk – long before symptoms appear.
The market launch of the WID-easy test in the UK generated a broad media response last week. Numerous leading British media outlets – including The Guardian, The Times, The Telegraph and ITV News London – reported extensively on the launch of the innovative test for detecting endometrial cancer. These publications reached millions of people and immediately made the test known nationwide.
On February 1, 2025, the WID®-easy Test was presented in the ORF program “Bewusst Gesund”. The report shows how this innovative epigenetic test is revolutionizing the early detection of uterine cancer and can spare affected women invasive procedures.
The WID®-easy PCR Test Kit has received marketing authorization for the UK through registration of the IVD with the Medicines and Healthcare products Regulatory Agency (MHRA) and confirmation that the WID®-easy PCR Kit, manufactured by Sola Diagnostics GmbH, meets all applicable regulatory requirements under the UK Medical Devices Regulations 2002 (SI 2002 No. 618, as amended) (UK MDR 2002).
Silvia Gamper’s experience with postmenopausal bleeding highlights the importance of accessible, less burdensome healthcare solutions for women.
The authors investigated the ability of WID-qEC testing to detect endometrial and cervical cancer in black women in Ghana who presented with abnormal uterine bleeding.